Adalank Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Adalank dosing — protocols, safety, and where to buy.
Dose Range
200-1200 mcg per dose (intranasal or subcutaneous), 1-2x daily
Frequency
Once or twice daily during cycles. Every-other-day protocols also documented.
Cycle Length
21-30 day cycles, with 7-14 day washouts between cycles. Avoid chronic continuous dosing.
Half-Life
~72 hours functional receptor binding (extrapolated from Adamax kinetic claims). Serum half-life unknown — no published pharmacokinetic data.
Administration Routes
Quick Reconstitution Calculator
Calculate syringe units instantly
Syringe Draw
10.0 units
2500 mcg/ml · 0.100 ml draw
Dosing Protocols
Beginner
- 200-400 mcg/day intranasal, once daily, 14 days
Intermediate
- 400-800 mcg/day, 1-2x daily, 21-30 days on / 7-14 off
Advanced
- 800-1,200 mcg/day, 2x daily, 30-day cycles
Weight-Based Dosing
Commonly Stacked With
Adalank is itself a stack (Adamax + Selank chemistry in one molecule), so additional stacking should be done conservatively to avoid receptor-level overlap.
Reasonable pairings:
- Cerebrolysin — neurotrophic amplification. The peptide fragment mix in Cerebrolysin layers cleanly on top of Adalank's BDNF/TrkB signal without direct receptor overlap.
- Dihexa — angiotensin-IV-derived synaptogenic. Complementary mechanism (HGF signaling) rather than overlapping with the BDNF or GABA pathways Adalank already covers.
- BPC-157 — neuroprotective baseline. Pairs with cognitive enhancers via dopaminergic system stabilization. No mechanistic overlap.
- Methylene Blue — mitochondrial cofactor for general cognitive support. Different mechanism layer.
Avoid stacking with:
- Adamax — Adalank already contains the Adamax pharmacophore. Stacking is redundant and risks D2 desensitization.
- Selank — same reason: Adalank already contains the Selank pharmacophore.
- Semax, N-Acetyl Semax Amidate, P-21 — overlapping BDNF / TrkB / D2 signaling. Use one or the other.
- Benzodiazepines — additive GABAergic effects, potential for impaired alertness and inverted "alert calm" profile.
Cycle architecture:
Recommended 30-day cycles followed by 14-day washouts. Avoid chronic continuous dosing — receptor desensitization at both the BDNF/TrkB and GABAergic ends is a theoretical concern given the multi-mechanism profile, and there is no long-term safety data to draw on.
Side Effects & Safety
Contraindications
**Absolute:** - Pregnancy and lactation — no safety data, multi-mechanism profile creates compounded unknowns - Active psychiatric instability (acute mania, psychosis) — dopaminergic component may exacerbate - Pediatric use — not characterized in any age group below adult - Known hypersensitivity to peptide injections or any constituent peptide **Relative (caution):** - Bipolar disorder (any phase) — dopaminergic D2 modulation may destabilize mood cycling - Uncontrolled hypertension — community reports of mild BP elevation at higher doses - Concurrent benzodiazepines or other GABAergic sedatives — additive effects on alertness - Concurrent MAOI therapy — theoretical interaction via dopaminergic component - Recent head trauma — no data; precautionary - Sleep disorders — late-day dosing can worsen insomnia; restrict dosing to before noon if sleep is fragile **Substance interactions to avoid:** - Stimulants (amphetamines, methylphenidate) — additive dopaminergic load - Recreational dopaminergic compounds — same concern **Stack overlaps to avoid:** - Semax, Selank, Adamax, P-21 at full simultaneous doses — Adalank already contains the Adamax + Selank pharmacophores
Additional Notes
Adalank dosing follows a similar pattern to Selank and Adamax — micrograms, not milligrams. Vendor product labeling varies; double-check vial concentration before reconstitution because the hybrid molecule can be sold at concentrations between Selank (5-10 mg vials) and Adamax (2-10 mg vials).
Intranasal protocol (most common):
- Reconstitute lyophilized peptide in bacteriostatic water to a known concentration (often 100 mcg per spray when properly mixed)
- 2-4 sprays per session, once or twice daily during cycles
- Effects build over 7-10 days; subjective peak is typically reported in weeks 2-3 of a cycle
Subcutaneous protocol (less common but documented):
- 200-1200 mcg per injection, 1-2x daily
- Faster onset than intranasal but the duration of effect is similar given the hybrid molecule's claimed extended receptor binding
What to avoid:
- Late-evening dosing (the Adamax component can disrupt sleep at higher doses)
- Continuous chronic dosing without washouts (receptor desensitization is a theoretical concern given the multi-mechanism profile)
- Combining at full doses with overlapping family compounds (Semax, Selank, Adamax, P-21)
Stability: After reconstitution, store in the refrigerator and use within 28 days. Adalank should not be frozen post-reconstitution — repeated freeze-thaw cycles degrade the peptide bonds.
Frequently Asked Questions
What is the recommended Adalank dosage?
The typical dose range for Adalank is 200-1200 mcg per dose (intranasal or subcutaneous), 1-2x daily. It is usually administered Once or twice daily during cycles. Every-other-day protocols also documented.. Always start with the lowest effective dose.
How often should I take Adalank?
Once or twice daily during cycles. Every-other-day protocols also documented.
Does Adalank need to be cycled?
Yes, typical cycle length is 21-30 day cycles, with 7-14 day washouts between cycles. Avoid chronic continuous dosing..
What are Adalank side effects?
**Reported (anecdotal, no formal trials):** - **Headache** — most commonly reported side effect, typically dose-related and self-limiting within 1-3 days. More common with intranasal route at higher doses. - **Transient insomnia** — if dosed in the evening. Restrict to morning / early afternoon if sleep is sensitive. - **Nasal irritation** — intranasal route only. Usually resolves within the first week of use or with dilution to a lower per-spray concentration. - **Mild mood elevation / irritability** — typically positive but can tip into restlessness at higher doses or in users sensitive to dopaminergic stimulation. - **Mild BP elevation** — anecdotal. Monitor if you have baseline hypertension. - **Increased dream activity** — common with Selank-family compounds and reported with Adalank as well. Usually benign. **No reported serious adverse events** in publicly available community datasets — but this is not a formal safety conclusion. The absence of SAEs reflects unregulated underreporting, not formal safety clearance. **No long-term safety data exists.** Multi-month or multi-year exposure consequences are entirely uncharacterized. Cycling protocols (21-30 days on, 7-14 days off) are a precautionary mitigation, not a validated safe-use pattern. **If side effects emerge:** - Headache or insomnia: lower dose by 50%, restrict to morning dosing - Mood instability or anxiety: discontinue immediately and consult a clinician - Persistent nasal irritation: switch to subcutaneous route or discontinue - BP elevation: discontinue and monitor **Reporting:** Adalank does not appear in FDA MedWatch or any major adverse event database. Community reporting via Reddit (r/Nootropics, r/Peptides) is the de facto safety signal but is heavily biased by self-selection.
Where can I buy Adalank?
Visit our vendor directory to find trusted sources for Adalank.
Adalank Full Profile
Research data, mechanisms, and pricing
Interaction Checker
Check drug & compound interactions
Related Dosage Guides
All GuidesFree 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
